Evidence map›Paper›PMID 35630429›Full record

ArticleMicroorganisms2022

Early Corticosteroid Therapy May Increase Ventilator-Associated Lower Respiratory Tract Infection in Critically Ill Patients with COVID-19: A Multicenter Retrospective Cohort Study.

Jean-Baptiste Mesland, Eric Carlier, Bruno François, Nicolas Serck, Ludovic Gerard, Charlotte Briat, Michael Piagnerelli, Pierre-François Laterre, On Behalf Of The Covcorvap Collaboration Group

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jean-Baptiste MeslandCritical Care Department, Cliniques Universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium.ORCID 0000-0002-8974-4991
Eric CarlierIntensive Care, CHU-Charleroi Marie Curie, Université Libre de Bruxelles, 6042 Charleroi, Belgium.
Bruno FrançoisICU Department and Inserm CIC 1435 & UMR 1092, CHU Dupuytren, 87000 Limoges, France.
Nicolas SerckUnité de Soins Intensifs, Clinique Saint-Pierre, 1340 Ottignies, Belgium.ORCID 0000-0001-5486-7812
Ludovic GerardCritical Care Department, Cliniques Universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium.
Charlotte BriatICU Department and Inserm CIC 1435 & UMR 1092, CHU Dupuytren, 87000 Limoges, France.
Michael PiagnerelliIntensive Care, CHU-Charleroi Marie Curie, Université Libre de Bruxelles, 6042 Charleroi, Belgium.
Pierre-François LaterreCritical Care Department, Cliniques Universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium.
On Behalf Of The Covcorvap Collaboration Group
Cliniques Universitaires Saint-Luc · BEInserm · FRUniversité Libre de Bruxelles · BEClinique Saint Pierre · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic has put significant pressure on hospitals and in particular on intensive care units (ICU). Some patients develop acute hypoxemic respiratory failure with profound hypoxia, which likely requires invasive mechanical ventilation during prolonged periods. Corticosteroids have become a cornerstone therapy for patients with severe COVID-19, though only little data are available regarding their potential harms and benefits, especially concerning the risk of a ventilator-associated lower respiratory tract infection (VA-LRTI).

methodsThis retrospective multicenter study included patients admitted in four ICUs from Belgium and France for severe COVID-19, who required invasive mechanical ventilation (MV). We compared clinical and demographic variables between patients that received corticosteroids or not, using univariate, multivariate, and Fine and Gray analyses to identify factors influencing VA-LRTI occurrence.

resultsFrom March 2020 to January 2021, 341 patients required MV for acute respiratory failure related to COVID-19, 322 of whom were included in the analysis, with 60.6% of them receiving corticosteroids. The proportion of VA-LRTI was significantly higher in the early corticosteroid group (63.1% vs. 48.8%,

conclusionsin our multicenter retrospective cohort of COVID-19 patients undergoing MV, early corticosteroid therapy was independently associated with VA-LRTI.

Indexed as

acute respiratory distress syndromecorticosteroidsCOVID-19SARS-CoV-2ventilator-associated lower respiratory tract infection

Identifiers

PMID35630429
PMCPMC9146632
OpenAlexW4229375399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.